Rajesh B Gandhi
Overview
Explore the profile of Rajesh B Gandhi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Badkar A, Gandhi R, Davis S, LaBarre M
Drug Des Devel Ther
. 2021 Jan;
15:159-170.
PMID: 33469268
Subcutaneous (SC) delivery of biologics has traditionally been limited to fluid volumes of 1-2 mL, with recent increases to volumes of about 3 mL. This injection volume limitation poses challenges...
2.
Krause M, Narang A, Barker G, Herzer S, Deshmukh S, Lan W, et al.
Eur J Pharm Biopharm
. 2018 Jul;
131:60-69.
PMID: 30031090
High concentration protein solutions are generally produced by spin column concentration (SCC) during early development and by tangential flow filtration (TFF) during later stages, when greater quantities of protein become...
3.
Zhou R, Schlam R, Yin S, Gandhi R, Adams M
J Pharm Sci
. 2013 Oct;
100(4):1605-6.
PMID: 24081479
No abstract available.
4.
Zhu Z, Chen Y, Ackerman M, Wang B, Wu W, Li B, et al.
J Pharm Biomed Anal
. 2013 May;
83:89-95.
PMID: 23708435
Fragmentation of monoclonal antibodies has been routinely observed in non-reducing SDS-PAGE, mainly due to disulfide-bond scrambling catalyzed by free sulfhydryl groups, resulting in a method induced artifact. To minimize this...
5.
Zhou R, Schlam R, Yin S, Gandhi R, Adams M
PDA J Pharm Sci Technol
. 2012 May;
66(3):221-35.
PMID: 22634588
Lay Abstract: Saccharides, including sucrose, trehalose, mannitol, and sorbitol, are commonly employed as stabilizers, cryoprotectants and/or tonicity adjusters in protein formulations. During thawing of formulated bulk drug substance, a white,...
6.
Fakes M, Vakkalagadda B, Qian F, Desikan S, Gandhi R, Lai C, et al.
Int J Pharm
. 2008 Dec;
370(1-2):167-74.
PMID: 19100319
BMS-488043 is an HIV-attachment inhibitor that exhibited suboptimal oral bioavailability upon using conventional dosage forms prepared utilizing micronized crystalline drug substance. BMS-488043 is classified as a Biopharmaceutics Classification System (BCS)...
7.
Gu C, Li H, Levons J, Lentz K, Gandhi R, Raghavan K, et al.
Pharm Res
. 2007 Mar;
24(6):1118-30.
PMID: 17385020
Purpose: To develop a statistical model for predicting effect of food on the extent of absorption (area under the curve of time-plasma concentration profile, AUC) of drugs based on physicochemical...
8.
Gu C, Rao D, Gandhi R, Hilden J, Raghavan K
J Pharm Sci
. 2005 Mar;
94(1):199-208.
PMID: 15761943
A novel multicompartment dissolution system was developed by modifying a conventional six-vessel United States Pharmacopoeia dissolution system to study the dissolution and possible precipitation of poorly soluble weak bases after...
9.
Gu C, Li H, Gandhi R, Raghavan K
Int J Pharm
. 2004 Sep;
283(1-2):117-25.
PMID: 15363508
The success rate of discovering new polymorphs by crystallization from solution may be increased if solvents with diverse properties are used during initial polymorph screening. In this study, eight solvent...
10.
Gu C, Gandhi R, Tay L, Zhou S, Raghavan K
Int J Pharm
. 2003 Dec;
269(1):195-202.
PMID: 14698591
BMS-480188 is a weak base. The aqueous solubility of BMS-480188 is 0.036 mg/ml at pH 6.5 at 37 degrees C. The mesylate salt of BMS-480188 was prepared to improve its...